Intelligent Medical Imaging
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
|Traded as||NASDAQ: IMII|
|Industry||Medical diagnostic equipment|
|Founded||Palm Beach Gardens, Florida (1989)|
|Headquarters||Palm Beach Gardens, Florida|
|Tyce Fitzmorris, President, CEO, Director|
|Products||Micro21, HSM, USM|
|Revenue||$3.8 million USD (1998)|
|$-13.7 million USD (1998)|
Number of employees
Intelligent Medical Imaging, also known as IMI or 'IMII' on Nasdaq, was based in Palm Beach Gardens, Florida. This company made automated medical equipment which was sold to hospitals and laboratories throughout the world. The company no longer exists.
IMI was established in June 1989, and went public in 1996, raising $35 million.
In the last full year of operation, 1998, IMI reported a gross annual income of $3.8 million and a net annual income of $-13.7 million.
In May 1999, the company was delisted from Nasdaq.
On November 29, 1999, IMI filed for Chapter 11 bankruptcy protection.
On May 10, 2000, all assets were sold to Triangle Biomedical Sciences, Inc., for $2 million.
The company no longer exists, and the original web site, www.imii.com, is no longer available.
The company's main product line was an automated cell and urine analyzer, sold under the name Micro21. The product could perform many different procedures, 9 of which were Food and Drug Administration (FDA) approved. At the time the company declared bankruptcy, several procedures had not yet received FDA approval.
The Micro21 could perform the following:
- white blood cell (WBC) differentials
- red blood cell morphology
- platelet estimates
- white blood cell (WBC) estimates
- reticulocyte counts
- cerebrospinal fluid (CSF) WBC differentials
- anti-nuclear antibody (ANA) screens and titers
- nuclear DNA (nDNA) screens
- animal differentials
- urinalysis (UA)
- gram staining
- bone marrow analysis
Hematology Slide Master
The Hematology Slide Master (HSM) was developed in the late 1990s just prior to bankruptcy. It was an automated tool for making and staining microscope-ready blood slides. Licensing deals were signed with other companies such as Bayer, but very few of these were produced and delivered.
The UriSlide Master (USM) was basically the same as the HSM, but for automated urine slides.
It is uncertain if any of these were completed and sold for revenue.
- Tyce Fitzmorris, President, CEO, Director
- Mike Smith, Vice President of Sales and Marketing
- Eric Espenhahn, Vice President of Product Development
- Jaime Pereira, Vice President of Engineering